| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1996;94:779-784.)
© 1996 American Heart Association, Inc.
Articles |
Short-term Hemodynamic Effects of Endothelin Receptor Blockade in Dogs With Chronic Heart Failure
the Department of Medicine, Division of Cardiovascular Medicine, Henry Ford Heart and Vascular Institute, Detroit, Mich.
Correspondence to Hani N. Sabbah, PhD, Henry Ford Hospital, 2799 W Grand Blvd, Detroit, MI 48202.
Background Plasma endothelin levels are increased in heart failure and may contribute to the increased peripheral vasoconstriction that characterizes this disease state. In the present study, we examined the effects of intravenous bosentan, a nonpeptide, competitive endothelin-1 receptor antagonist, on hemodynamics in dogs with chronic heart failure.
Methods and Results Chronic heart failure was produced in 11 dogs by multiple sequential intracoronary microembolization. At the time of study, left ventricular (LV) ejection fraction was 25±2%. Hemodynamic and echocardiographic measurements were made at baseline and at 15, 30, and 60 minutes after a bolus injection of bosentan (10 mg/kg). Bosentan had no significant effect on heart rate or mean aortic blood pressure. At 60 minutes, bosentan reduced LV end-diastolic pressure (17±2 versus 11±2 mm Hg; P<.05) and systemic vascular resistance (3891±379 versus 3071±346 dyne·s·cm-5; P<.05) compared with baseline and increased cardiac output (2.63±0.29 versus 3.33±0.46 L/min; P<.05), peak rate of change of LV pressure during isovolumic contraction and relaxation (1751±92 versus 2197±170 mm Hg/s; P<.05), and LV fractional shortening determined by echocardiography (30±2% versus 36±2%; P<.05).
Conclusions Short-term intravenous bosentan reduced systemic vascular resistance and improved overall LV performance in dogs with chronic heart failure. These results suggest that endothelin-1 receptor antagonists may be useful therapeutic agents in the treatment of heart failure.
Key Words: heart failure • endothelin • receptors
This article has been cited by other articles:
 |
|
 |
|
  M. Okajima, R. Parent, E. Thorin, and M. Lavallee Pathophysiological plasma ET-1 levels antagonize {beta}-adrenergic dilation of coronary resistance vessels in conscious dogs Am J Physiol Heart Circ Physiol, October 1, 2004; 287(4): H1476 - H1483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Noguchi, Z. Chen, S. P. Bell, L. Nyland, and M. M. LeWinter Endothelin receptor blockade has an oxygen-saving effect in Dahl salt-sensitive rats with heart failure Am J Physiol Heart Circ Physiol, October 1, 2003; 285(4): H1428 - H1434. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Chu, R. Takahashi, I. Norota, T. Miyamoto, Y. Takeishi, K. Ishii, I. Kubota, and M. Endoh Signal Transduction and Ca2+ Signaling in Contractile Regulation Induced by Crosstalk Between Endothelin-1 and Norepinephrine in Dog Ventricular Myocardium Circ. Res., May 16, 2003; 92(9): 1024 - 1032. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Clozel, C. Qiu, C.-S. Qiu, P. Hess, and J.-P. Clozel Short-term endothelin receptor blockade with tezosentan has both immediate and long-term beneficial effects in rats with myocardial infarction J. Am. Coll. Cardiol., January 2, 2002; 39(1): 142 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Tadano, J. Suzuki, K. Hanada, M. Nakao, R. Nakao, S. Uehara, H. Ohta, T. Miyauchi, and M. Nishikibe Pathophysiological Roles of Endogenous Endothelin-1 in Dogs with Chronic Heart Failure Produced by Rapid Right Ventricular Pacing J. Pharmacol. Exp. Ther., August 1, 2001; 298(2): 729 - 736. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. MacCarthy, N. C. Pegge, B. D. Prendergast, A. M. Shah, and P. H. Groves The physiological role of endogenous endothelin in the regulation of human coronary vasomotor tone J. Am. Coll. Cardiol., January 1, 2001; 37(1): 137 - 143. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-T. Shen, P. S Buie, J. J Lynch, S. M Krause, and X.-L. Ma Chronic therapy with an ETA/B receptor antagonist in conscious dogs during progression of congestive heart failure: Intracellular Ca2+ regulation and nitric oxide mediated coronary relaxation Cardiovasc Res, November 1, 2000; 48(2): 332 - 345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. MacCarthy, R. Grocott-Mason, B. D. Prendergast, and A. M. Shah Contrasting Inotropic Effects of Endogenous Endothelin in the Normal and Failing Human Heart : Studies With an Intracoronary ETA Receptor Antagonist Circulation, January 18, 2000; 101(2): 142 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Mishima, M. Tanimura, G. Suzuki, A. Todor, V. G. Sharov, S. Goldstein, and H. N. Sabbah Effects of long-term therapy with bosentan on the progression of left ventricular dysfunction and remodeling in dogs with heart failure J. Am. Coll. Cardiol., January 1, 2000; 35(1): 222 - 229. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Onishi, M. Ohno, W. C. Little, and C.-P. Cheng Endogenous Endothelin-1 Depresses Left Ventricular Systolic and Diastolic Performance in Congestive Heart Failure J. Pharmacol. Exp. Ther., March 1, 1999; 288(3): 1214 - 1222. [Abstract] [Full Text]
|
|
|
|
|
|
T. Inada, H. Fujiwara, K. Hasegawa, M. Araki, R. Yamauchi-Kohno, H. Yabana, T. Fujiwara, M. Tanaka, and S. Sasayama Upregulated expression of cardiac endothelin-1 participates in myocardial cell growth in Bio14.6 Syrian cardiomyopathic hamsters J. Am. Coll. Cardiol., February 1, 1999; 33(2): 565 - 571. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Iwanaga, Y. Kihara, K. Hasegawa, K. Inagaki, T. Yoneda, S. Kaburagi, M. Araki, and S. Sasayama Cardiac Endothelin-1 Plays a Critical Role in the Functional Deterioration of Left Ventricles During the Transition From Compensatory Hypertrophy to Congestive Heart Failure in Salt-Sensitive Hypertensive Rats Circulation, November 10, 1998; 98(19): 2065 - 2073. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W Moe, A. Albernaz, G. O Naik, M. Kirchengast, and D. J Stewart Beneficial effects of long-term selective endothelin type A receptor blockade in canine experimental heart failure Cardiovasc Res, September 1, 1998; 39(3): 571 - 579. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Choussat, L. Hittinger, F. Barbe, G. Maistre, A. Carayon, B. Crozatier, and J. Su Acute effects of an endothelin-1 receptor antagonist bosentan at different stages of heart failure in conscious dogs Cardiovasc Res, September 1, 1998; 39(3): 580 - 588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Suzuki, N. Ohte, Z.-M. Wang, D. L. Williams Jr., W. C. Little, and C.-P. Cheng Altered inotropic response of endothelin-1 in cardiomyocytes from rats with isoproterenol-induced cardiomyopathy Cardiovasc Res, September 1, 1998; 39(3): 589 - 599. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ohnishi, A. Wada, T. Tsutamoto, D. Fukai, and M. Kinoshita Comparison of the acute effects of a selective endothelin ETA and a mixed ETA/ETB receptor antagonist in heart failure Cardiovasc Res, September 1, 1998; 39(3): 617 - 624. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhang, J. R. Oliver, and J. D. Horowitz Endothelin B receptor-mediated vasoconstriction induced by endothelin A receptor antagonist Cardiovasc Res, September 1, 1998; 39(3): 665 - 673. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hoshino, R. Yamauchi, K. Kikkawa, H. Yabana, and S. Murata Pharmacological Profile of T-0201, a Highly Potent and Orally Active Endothelin Receptor Antagonist J. Pharmacol. Exp. Ther., August 1, 1998; 286(2): 643 - 649. [Abstract] [Full Text]
|
|
|
|
|
|
H. Shimoyama, H. N. Sabbah, M. Tanimura, S. Borzak, and S. Goldstein Short-Term Hemodynamic Effects of Mibefradil in Dogs With Chronic Heart Failure: Comparison With Diltiazem J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 746 - 752. [Abstract] [Full Text]
|
|
|
|
|
|
E. Ferrari, A. Talbodec, P. Vigne, and C. Frelin Evidence for receptor bound endothelin in renal but not in cardiac tissues from normal rats Cardiovasc Res, April 1, 1998; 38(1): 140 - 148. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. D. Borgeson, J. A. Grantham, E. E. Williamson, A. Luchner, M. M. Redfield, T. J. Opgenorth, and J. C. Burnett Jr Chronic Oral Endothelin Type A Receptor Antagonism in Experimental Heart Failure Hypertension, March 1, 1998; 31(3): 766 - 770. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Mulder, V. Richard, G. Derumeaux, M. Hogie, J. P. Henry, F. Lallemand, P. Compagnon, B. Mace, E. Comoy, B. Letac, et al. Role of Endogenous Endothelin in Chronic Heart Failure : Effect of Long-term Treatment With an Endothelin Antagonist on Survival, Hemodynamics, and Cardiac Remodeling Circulation, September 16, 1997; 96(6): 1976 - 1982. [Abstract] [Full Text]
|
|
|
|
|
|
J. N. Cohn Is There a Role for Endothelin in the Natural History of Heart Failure? Circulation, August 15, 1996; 94(4): 604 - 606. [Full Text]
|
|